Novo Nordisk ends partnership with Hims & Hers over concerns about unsafe Wegovy sales and FDA violations.
Tags: Novo Nordisk
Novo Nordisk CEO's Bold Vow: Full Commitment to Weight-Loss Pill as Wegovy Price Falls
Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing obesity drug market.
Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera
Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.
Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks
Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.
Costco Partners with Novo Nordisk to Sell Ozempic and Wegovy at Lower Cost
Costco teams up with Novo Nordisk to sell Ozempic and Wegovy at $499, making popular weight-loss drugs more affordable for members.
Latest News
Novo Nordisk's CagriSema helps patients lose over 20% body weight in late-stage obesity trial.
Novo Nordisk partners with Septerna in a $2.2 billion deal to develop oral treatments for obesity, type 2 diabetes, and other metabolic diseases.
Novo Nordisk reassures investors with strong growth forecasts, rising GLP-1 drug demand, and promising new treatments despite market challenges.
Novo Nordisk launches Wegovy in China, offering an effective weight-loss solution for about 180 million obese Chinese population, though not covered by insurance.
A new study reveals that semaglutide, a key ingredient in Ozempic and Wegovy, reduces the risk of dying from Covid-19 by 33%, [otentially boosting its market value.
Shares of pharmaceutical companies Novo Nordisk and Eli Lilly slid after Roche announced results from a promising early-stage trial for its proposed obesity drug.
A new study published in JAMA Ophthalmology suggests that taking Ozempic or Wegovy may increase the risk of developing a rare form of blindness.
President Joe Biden and Senator Bernie Sanders have urged Novo Nordisk and Eli Lilly to lower the prices of their popular weight loss drugs.
Novo Nordisk announced a $4.1 billion investment to build a new manufacturing plant in Clayton, North Carolina, to increase production capacity for its popular drugs Wegovy, Ozempic, and other injectable therapies.
